Close Menu

NEW YORK (GenomeWeb) – Trovagene announced today that it has signed an agreement to provide its Trovera urine-based circulating tumor DNA (ctDNA) biomarker test and related services to AstraZeneca for use in a biomarker study.

Under the terms of the deal, AstraZeneca will use Trovagene's Trovera EGFR urine liquid biopsy test in an open-label prospective biomarker study evaluating whether blood and urine testing in combination is as effective as tissue testing in identifying epidermal growth factor receptor T790M mutation status.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.